Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy.

Naunyn-Schmiedeberg's archives of pharmacology - 1 Oct 2024

Chao Wan-Ru, Lee Ming-Yung, Sheu Gwo-Tarng, Lee Yi-Ju, Shen Huang-Pin, Han Chih-Ping

Abstract excerpt

Recent clinical evidence shows that the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) can successfully treat patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). We aimed to characterize HER2 mutations in cervical neuroendocrine carcinoma (NEC) among Taiwanese women to provide the rationale for exploring T-DXd as a tumor-agnostic targeted therapy option. We analyzed 12 archived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Neuroendocrine

Share to Immunoconjugates

Share to Receptor, ErbB-2

Share to Taiwan

Share to Trastuzumab

Share to Uterine Cervical Neoplasms

Source

Identifiers

PMID: 38689071
DOI: 10.1007/s00210-024-03066-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy.PMID 38689071Read ↗

Patient-derived organoids assist personalized treatment for a patient with multiple metastatic neuroendocrine carcinoma of the cervixSemantic proximity Read ↗

[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification: A Case Report].Semantic proximity Read ↗

Neuroendocrine Carcinoma of the Cervix: Clinicopathologic Study and Review of the LiteratureSemantic proximity Read ↗

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancerSemantic proximity Read ↗

Tumor genome and microenvironment alteration by trastuzumab deruxtecan as neoadjuvant therapy for HER2-mutant NSCLC.Semantic proximity Read ↗

Tumor Genome and Microenvironment Alteration by Trastuzumab Deruxtecan as Neoadjuvant Therapy for HER2 Mutant NSCLCSemantic proximity Read ↗

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerSemantic proximity Read ↗

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.Semantic proximity Read ↗

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialSemantic proximity Read ↗

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Semantic proximity Read ↗

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.Semantic proximity Read ↗

Durable Response to Trastuzumab Deruxtecan in a Patient with Urothelial Cancer and ERBB2 Mutation: A Case ReportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.